The pipeline of new antibiotics to curb the antimicrobial resistance crisis remains inadequate. Belgium is developing a new antibiotic class, but success depends on securing vital support and incentives.
Antimicrobial resistance is on the rise, prompting the Swedish government to invite the European Centre for Disease Prevention and Control and the European Commission to review Sweden’s AMR strategy.
“What kind of europe do we want? A Europe that puts patients’ needs at the forefront, or that prioritises the interests of big pharma?” says Greens health expert Tilly Metz
How do you envisage the creation of a product which you ideally don’t want to use? That was the focal point of the Belgian presidency’s high-level meeting on how the EU should coordinate its response to antibiotic resistance (AMR).
An alarming new ECDC survey reveals that healthcare-associated infections (HAI) and antibiotic use are on the rise, increasing patient safety risks across Europe.
A new antibiotic against gram-negative bacteria hasn’t been developed since the 1970s. Now, a European research team led by Swedish scientists has discovered multi-drug-resistant bug-killing compounds that could lead to a new class of antibiotics.
Professor Peter Piot, Belgium’s special advisor to European Commission president Ursula von der Leyen on European and Global Health Security, has called antimicrobial resistance (AMR) a crisis already underway and gaining importance.
The EU is falling short of reaching the antimicrobial consumption targets for 2030 with some member states even backtracking from 2019 numbers, a new report by the European Centre for Disease Prevention and Control has found.
With collective determination, an open mindset and willingness to do things differently, Europe can set an example in the fight against antimicrobial resistance. Huw Tippett, CEO of Shionogi Europe, calls for collective action ahead of the European Health Forum, Gastein.
The revamp of the bloc's regulatory framework for pharmaceuticals, presented by the European Commission on Wednesday (26 April), features a new and somewhat controversial system of incentives to promote the development of new antimicrobials.
The European Commission will call for "cooperation between different stakeholders to bring about positive change" in the pharmaceutical sector, according to a leaked communication accompanying the revision of the EU's drug framework.
With only a few weeks before unveiling the EU's revamped framework for pharmaceuticals, Health Commissioner Stella Kyriakides described the main drivers of the much-awaited reform, stressing the importance of finding the balance between patients' and industry's interests.
Sales of antibiotics used for animal use have almost halved between 2011-2021, according to a new report issued by the European Medicines Agency (EMA), putting the EU on track to attain its ambitions, but with a warning that the sector should not become complacent.
As deaths due to antimicrobial resistance (AMR) rise, public health actions aimed at tackling AMR are insufficient, according to a report by the European Centre for Disease Prevention and Control (ECDC) published Thursday (17 November).
Animal transportation times should be cut to reduce the risk of spreading antimicrobial resistance, according to a new scientific opinion from the European Food Safety Authority (EFSA).
The EU member states have now formally given their support to the list of antimicrobials reserved for human use proposed by the Commission. Despite this, the criticism has not died down.
The COVID-19 crisis has underscored that there is no way to ensure human and animal health without wider consideration of environmental health, Monique Eloit, Director General of the World Organisation for Animal Health, told EURACTIV in an interview.
Download PDF
In the wake of the COVID pandemic, and with the race against antibiotic resistance becoming ever more pressing, it is more important than ever to make the 'One Health' approach a reality.
The European Commission’s list of antimicrobials to be reserved for human use only is based on sound scientific evidence, an EU official stressed after EU lawmakers reiterated their objection to the act implementing it.
European lawmakers are still not impressed by the EU executive's strong defence of its stance on the disputed antimicrobial colistin, as disagreements surrounding the list of antimicrobials to be reserved for human use continue.
EU and national policies are not ambitious enough to reach the bloc's goal of halving antibiotic use in livestock farming by 2030, according to campaigners, who warn that without sufficient action, humans will also be at risk from antimicrobial resistance.
Health commissioner Stella Kyriakides reaffirmed support for the European Medicines Agency (EMA)'s set of recommendations for antimicrobials to be reserved for humans only despite criticism over the non-inclusion of colistin, an antibiotic used in veterinary medicine.
We need better tools to end TB and AMR, and the EU can and must lead these efforts, writes Nicolae Ștefănuță.
European lawmakers did not hold back in their criticism of the new European Medicines Agency (EMA) recommendations for antimicrobials to be reserved for human use at a committee meeting on Tuesday (15 March).
